ME Therapeutics Holdings Inc. (CSE: METX)

Market Cap	141.81M
Revenue	n/a
Net Income	n/a
Shares Out	23.63M
EPS	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Average Volume	445
Open	6.00
Previous Close	6.29
Day's Range	6.00 - 6.00
52-Week Range	0.75 - 7.50
Beta	n/a
RSI	68.85
Earnings Date	n/a

About ME Therapeutics Holdings

ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno‐oncology. Its lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. The company also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutics...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: METX